These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 158847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
    Gurewich V, Hyde E, Lipinski B.
    Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR, Collen D.
    Haemostasis; 1986 Oct; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract] [Full Text] [Related]

  • 6. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L, Boreisha IG, Arzadon L, Robbins KC.
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R, Fears R, Smith RA.
    Biochem J; 1987 Oct 15; 247(2):395-400. PubMed ID: 3122725
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O, Rijken DC, Collen D.
    Thromb Haemost; 1981 Jun 30; 45(3):225-9. PubMed ID: 7025339
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R, Black J, Gurewich V.
    J Clin Invest; 1988 Mar 30; 81(3):853-9. PubMed ID: 2963831
    [Abstract] [Full Text] [Related]

  • 14. Fibrinolysis--a review.
    Kane KK.
    Ann Clin Lab Sci; 1984 Mar 30; 14(6):443-9. PubMed ID: 6239587
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. QUANTITATIVE ESTIMATION OF UROKINASE AND BACTERIAL PLASMINOGEN ACTIVATORS USING A FIBRIN SUBSTRATE FORMED FROM PLASMINOGEN-FREE FIBRINOGEN.
    ANDERSON AJ.
    Biochim Biophys Acta; 1963 Aug 13; 74():554-7. PubMed ID: 14071603
    [No Abstract] [Full Text] [Related]

  • 18. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS, Rozenfeld MA, Leonova VB.
    Thromb Res; 1995 Apr 15; 78(2):173-87. PubMed ID: 7482434
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.